Zacks Investment Research cut shares of GENMAB AS DKK1 (OTCMKTS:GNMSF) from a buy rating to a hold rating in a research report sent to investors on Monday.

According to Zacks, “Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. In addition, Genmab has developed UniBody, a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Europe and the US. “

Separately, JPMorgan Chase & Co. started coverage on GENMAB AS DKK1 in a report on Tuesday, June 21st. They set a neutral rating for the company.

GENMAB AS DKK1 (OTCMKTS:GNMSF) opened at 158.25 on Monday. The company’s 50 day moving average price is $173.07 and its 200 day moving average price is $158.09. GENMAB AS DKK1 has a 12 month low of $93.25 and a 12 month high of $183.00. The stock has a market cap of $9.47 billion, a PE ratio of 93.69 and a beta of 0.89.

Receive News & Ratings for GENMAB AS DKK1 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENMAB AS DKK1 and related companies with MarketBeat.com's FREE daily email newsletter.